PTC Therapeutics Inc (NASDAQ:PTCT) price on Friday, December 27, fall -1.33% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $45.23.
A look at the stock’s price movement, the close in the last trading session was $45.84, moving within a range at $44.7 and $46.11. The beta value (5-Year monthly) was 0.628. Turning to its 52-week performance, $54.16 and $23.58 were the 52-week high and 52-week low respectively. Overall, PTCT moved -1.70% over the past month.
PTC Therapeutics Inc’s market cap currently stands at around $3.49 billion, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 214.24M for the company’s revenue for the quarter, with a low and high estimate of 172.77M and 370.3M respectively. The average forecast suggests down to a -30.23% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 795.38M, representing a -15.19% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PTCT is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 2 recommend PTCT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PTCT’s current price about -4.63% and 2.86% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 48.32, while 7-day volatility ratio is 3.66% and 5.00% in the 30-day chart. Further, PTC Therapeutics Inc (PTCT) has a beta value of 0.62, and an average true range (ATR) of 2.31. Analysts have given the company’s stock an average 52-week price target of $47, forecast between a low of $45 and high of $52. Looking at the price targets, the low is 0.51% off current price level while to achieve the yearly target high, price needs to move -14.97%. Nonetheless, investors will most likely welcome a -3.91% jump to $47 which is the analysts’ median price.
If we refocus on PTC Therapeutics Inc (NASDAQ:PTCT), historical trading data shows that trading volumes averaged 0.59 over the past 10 days and 816.17K over the past 3 months. The company’s latest data on shares outstanding shows there are 76.95 million shares.
The 3.45% of PTC Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 101.75% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.6 million on 2024-11-29, giving us a short ratio of 6.3. The data shows that as of 2024-11-29 short interest in PTC Therapeutics Inc (PTCT) stood at 927.00005 of shares outstanding, with shares short falling to 4.89 million registered in 2024-10-31. Current price change has pushed the stock 64.11% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PTCT stock continues to rise going into the next quarter.
